There was another patent that was 'published' on the same day the cardio protection patent was filed (originally applied for back in 2019).
"This invention is directed to an improved method for preparing bisantrene for intravenous administration and to preparations of bisantrene for intravenous administration, as well as to methods for treatment of malignancies treatable by administration of bisantrene, which can include administration of additional antineoplastic agents."
RAC probably further advanced with the IV IP than most would expect.
Ann: Zantrene highly effective in Melanoma preclinical study, page-175
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.055(3.61%) |
Mkt cap ! $250.5M | |||
| Open | High | Low | Value | Volume |
| $1.53 | $1.58 | $1.46 | $143.9K | 96.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 230 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 550 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |